Peptide Encyclopedia / Ovagen
EncyclopediaOvagen is a short synthetic peptide, commonly cited as the tripeptide Glu-Asp-Leu, from the Khavinson bioregulator family and marketed for liver and digestive support. The FDA has not approved it, it trades gray-market in the US, and evidence stays weak, based on Russian preclinical work. Educational only, not medical advice.
| Category | Longevity / Anti-aging |
| Regulatory status | Not FDA-approved; research chemical / gray-market in the US. |
A short synthetic peptide (commonly cited as the tripeptide Glu-Asp-Leu) from the Khavinson bioregulator family, marketed for liver and digestive/protein-synthesis support. Proposed (unproven) mechanism is tissue-specific modulation of gene expression.
sources are inconsistent about Ovagen's exact organ target and sequence.)
uncertain / limited human pharmacokinetic data; presumed rapid clearance but no rigorous human PK exists.
Not FDA-approved; research chemical / gray-market in the US. Not an FDA-approved drug; sold within Russia in the bioregulator/supplement context only.
Human safety data are minimal and largely Russian-sourced. Rapid clearance suggests low acute risk but is not a substitute for controlled safety data. Gray-market purity/identity unverified.
Weak/limited evidence base with notable inconsistency across sources regarding target/sequence; predominantly Russian preclinical work and little to no independent Western human data.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Ovagen may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
